Trials / Completed
CompletedNCT06411912
A Study of NIDO-361 in Patients With SBMA
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Nido Biosciences, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NIDO-361 | Tablets containing 100mg of NIDO-361 for oral administration. |
| DRUG | Placebo | Placebo oral tablets |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2025-10-22
- Completion
- 2025-10-22
- First posted
- 2024-05-13
- Last updated
- 2026-03-03
- Results posted
- 2026-03-03
Locations
5 sites across 4 countries: Denmark, Italy, South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT06411912. Inclusion in this directory is not an endorsement.